Technical Analysis for NVAX - Novavax, Inc.

Grade Last Price % Change Price Change
grade F 0.521 2.16% 0.01
NVAX closed up 2.16 percent on Monday, March 18, 2019, on 1.7 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical NVAX trend table...

Date Alert Name Type % Chg
Mar 18 Narrow Range Bar Range Contraction 0.00%
Mar 18 Earnings Movers Other 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Oversold Stochastic Weakness 0.00%
Mar 15 Narrow Range Bar Range Contraction 2.16%
Mar 15 Wide Bands Range Expansion 2.16%
Mar 15 Oversold Stochastic Weakness 2.16%
Mar 14 1,2,3 Retracement Bearish Bearish Swing Setup -1.70%
Mar 14 Boomer Sell Setup Bearish Swing Setup -1.70%
Mar 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.70%

Older signals for NVAX ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing recombinant protein nanoparticle vaccines to address a range of infectious diseases. The company's technology platform is based on proprietary recombinant vaccine technology that includes virus-like particles (VLPs) and recombinant protein micelle vaccines. Its vaccine candidates target seasonal influenza, pandemic (H5N1) influenza, and respiratory syncytial virus (RSV). The company, through its joint venture, CPL Biologics Private Limited, engages in developing seasonal and pandemic influenza, and rabies vaccine candidates. The company has a licensing agreement with LG Life Sciences, Ltd. to use the company's VLP technology to develop and sell the influenza vaccines in South Korea and other countries; and a clinical development agreement with PATH Vaccine Solutions to develop RSV vaccine candidate. The company was founded in 1987 and is headquartered in Rockville, Maryland.
Medicine Biopharmaceutical Medical Specialties Infectious Diseases Influenza Vaccination Vaccines Influenza Vaccine Rabies Seasonal Influenza H5n1 Clinical Trials
Is NVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 2.58
52 Week Low 0.49
Average Volume 15,894,790
200-Day Moving Average 1.6816
50-Day Moving Average 1.7452
20-Day Moving Average 1.075
10-Day Moving Average 0.536
Average True Range 0.116
ADX 42.88
+DI 15.4453
-DI 50.9006
Chandelier Exit (Long, 3 ATRs ) 1.872
Chandelier Exit (Short, 3 ATRs ) 0.838
Upper Bollinger Band 2.4608
Lower Bollinger Band -0.3108
Percent B (%b) 0.3
BandWidth 257.823256
MACD Line -0.4119
MACD Signal Line -0.3917
MACD Histogram -0.0202
Fundamentals Value
Market Cap 151.04 Million
Num Shares 290 Million
EPS -0.77
Price-to-Earnings (P/E) Ratio -0.68
Price-to-Sales 13.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.59
Resistance 3 (R3) 0.59 0.58 0.58
Resistance 2 (R2) 0.58 0.56 0.57 0.57
Resistance 1 (R1) 0.55 0.55 0.56 0.54 0.57
Pivot Point 0.53 0.53 0.54 0.53 0.53
Support 1 (S1) 0.50 0.51 0.52 0.50 0.47
Support 2 (S2) 0.48 0.50 0.48 0.47
Support 3 (S3) 0.46 0.48 0.46
Support 4 (S4) 0.45